TocilizumabV1, Main, Exploration, bibRecord, 000241

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

Identifieur interne : 000241 ( Main/Exploration ); précédent : 000240; suivant : 000242

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

Auteurs : Nick Bansback ; Jeffrey R. Curtis ; Jie Huang ; Zeling He ; Michael Evans ; Tracy Johansson ; Kaleb Michaud ; Gabriela Schmajuk ; Katherine P. Liao

Source :

ACR Open Rheumatology [ 2578-5745 ] ; 2020.

RBID : PMC:7011419

Abstract

Objective

It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility. This study evaluates biosimilar tumor necrosis factor inhibitor (TNFi) utilization across rheumatology practices in the United States and compares whether patients initiating biosimilars remain on these treatments at least as long as new initiators of bio‐originators.

Methods

We identified a cohort of patients initiating a TNFi biosimilar between January 2017 and September 2018 from an electronic health record registry containing data from 218 rheumatology practices and over 1 million rheumatology patients in the United States. We also identified a cohort of patients who initiated the bio‐originator TNFi during the same period. We calculated the proportion of biosimilar prescriptions compared with other TNFi's and compared persistence on these therapies, adjusting for age, sex, diagnoses codes, and insurance type.

Results

We identified 909 patients prescribed the biosimilar infliximab‐dyyb, the only biosimilar prescribed, and 4413 patients with a new prescription for the bio‐originator infliximab. Biosimilar patients tended to be older, have a diagnosis code for rheumatoid arthritis, and covered by Medicare insurance. Over the study period, biosimilar prescriptions reached a maximum of 3.5% of all TNFi prescriptions. Patients persisted on the biosimilar at least as long as the bio‐originator infliximab (hazard ratio [HR] 0.83, P = 0.07).

Conclusion

The uptake of biosimilars in the United States remains low despite persistence on infliximab‐dyyb being similar to the infliximab bio‐originator. These results add to clinical studies that should provide greater confidence to patients and physicians regarding biosimilar use.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011419

DOI: 10.1002/acr2.11106
PubMed: 32043831
PubMed Central: 7011419

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patterns of Tumor Necrosis Factor Inhibitor (<styled-content style="fixed-case" toggle="no">TNF</styled-content>
i) Biosimilar Use Across United States Rheumatology Practices</title>
<author><name sortKey="Bansback, Nick" sort="Bansback, Nick" uniqKey="Bansback N" first="Nick" last="Bansback">Nick Bansback</name>
<affiliation><nlm:aff id="acr211106-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R." last="Curtis">Jeffrey R. Curtis</name>
<affiliation><nlm:aff id="acr211106-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Huang, Jie" sort="Huang, Jie" uniqKey="Huang J" first="Jie" last="Huang">Jie Huang</name>
<affiliation><nlm:aff id="acr211106-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="He, Zeling" sort="He, Zeling" uniqKey="He Z" first="Zeling" last="He">Zeling He</name>
<affiliation><nlm:aff id="acr211106-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Evans, Michael" sort="Evans, Michael" uniqKey="Evans M" first="Michael" last="Evans">Michael Evans</name>
<affiliation><nlm:aff id="acr211106-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Johansson, Tracy" sort="Johansson, Tracy" uniqKey="Johansson T" first="Tracy" last="Johansson">Tracy Johansson</name>
<affiliation><nlm:aff id="acr211106-aff-0005"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Michaud, Kaleb" sort="Michaud, Kaleb" uniqKey="Michaud K" first="Kaleb" last="Michaud">Kaleb Michaud</name>
<affiliation><nlm:aff id="acr211106-aff-0006"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Schmajuk, Gabriela" sort="Schmajuk, Gabriela" uniqKey="Schmajuk G" first="Gabriela" last="Schmajuk">Gabriela Schmajuk</name>
<affiliation><nlm:aff id="acr211106-aff-0007"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Liao, Katherine P" sort="Liao, Katherine P" uniqKey="Liao K" first="Katherine P." last="Liao">Katherine P. Liao</name>
<affiliation><nlm:aff id="acr211106-aff-0008"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">32043831</idno>
<idno type="pmc">7011419</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011419</idno>
<idno type="RBID">PMC:7011419</idno>
<idno type="doi">10.1002/acr2.11106</idno>
<date when="2020">2020</date>
<idno type="wicri:Area/Pmc/Corpus">000518</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000518</idno>
<idno type="wicri:Area/Pmc/Curation">000518</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000518</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000157</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000157</idno>
<idno type="wicri:Area/Ncbi/Merge">002905</idno>
<idno type="wicri:Area/Ncbi/Curation">002905</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002905</idno>
<idno type="wicri:Area/Main/Merge">000241</idno>
<idno type="wicri:Area/Main/Curation">000241</idno>
<idno type="wicri:Area/Main/Exploration">000241</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Patterns of Tumor Necrosis Factor Inhibitor (<styled-content style="fixed-case" toggle="no">TNF</styled-content>
i) Biosimilar Use Across United States Rheumatology Practices</title>
<author><name sortKey="Bansback, Nick" sort="Bansback, Nick" uniqKey="Bansback N" first="Nick" last="Bansback">Nick Bansback</name>
<affiliation><nlm:aff id="acr211106-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R." last="Curtis">Jeffrey R. Curtis</name>
<affiliation><nlm:aff id="acr211106-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Huang, Jie" sort="Huang, Jie" uniqKey="Huang J" first="Jie" last="Huang">Jie Huang</name>
<affiliation><nlm:aff id="acr211106-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="He, Zeling" sort="He, Zeling" uniqKey="He Z" first="Zeling" last="He">Zeling He</name>
<affiliation><nlm:aff id="acr211106-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Evans, Michael" sort="Evans, Michael" uniqKey="Evans M" first="Michael" last="Evans">Michael Evans</name>
<affiliation><nlm:aff id="acr211106-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Johansson, Tracy" sort="Johansson, Tracy" uniqKey="Johansson T" first="Tracy" last="Johansson">Tracy Johansson</name>
<affiliation><nlm:aff id="acr211106-aff-0005"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Michaud, Kaleb" sort="Michaud, Kaleb" uniqKey="Michaud K" first="Kaleb" last="Michaud">Kaleb Michaud</name>
<affiliation><nlm:aff id="acr211106-aff-0006"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Schmajuk, Gabriela" sort="Schmajuk, Gabriela" uniqKey="Schmajuk G" first="Gabriela" last="Schmajuk">Gabriela Schmajuk</name>
<affiliation><nlm:aff id="acr211106-aff-0007"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Liao, Katherine P" sort="Liao, Katherine P" uniqKey="Liao K" first="Katherine P." last="Liao">Katherine P. Liao</name>
<affiliation><nlm:aff id="acr211106-aff-0008"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">ACR Open Rheumatology</title>
<idno type="eISSN">2578-5745</idno>
<imprint><date when="2020">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="acr211106-sec-0001"><title>Objective</title>
<p>It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility. This study evaluates biosimilar tumor necrosis factor inhibitor (TNFi) utilization across rheumatology practices in the United States and compares whether patients initiating biosimilars remain on these treatments at least as long as new initiators of bio‐originators.</p>
</sec>
<sec id="acr211106-sec-0002"><title>Methods</title>
<p>We identified a cohort of patients initiating a TNFi biosimilar between January 2017 and September 2018 from an electronic health record registry containing data from 218 rheumatology practices and over 1 million rheumatology patients in the United States. We also identified a cohort of patients who initiated the bio‐originator TNFi during the same period. We calculated the proportion of biosimilar prescriptions compared with other TNFi's and compared persistence on these therapies, adjusting for age, sex, diagnoses codes, and insurance type.</p>
</sec>
<sec id="acr211106-sec-0003"><title>Results</title>
<p>We identified 909 patients prescribed the biosimilar infliximab‐dyyb, the only biosimilar prescribed, and 4413 patients with a new prescription for the bio‐originator infliximab. Biosimilar patients tended to be older, have a diagnosis code for rheumatoid arthritis, and covered by Medicare insurance. Over the study period, biosimilar prescriptions reached a maximum of 3.5% of all TNFi prescriptions. Patients persisted on the biosimilar at least as long as the bio‐originator infliximab (hazard ratio [HR] 0.83, <italic>P</italic>
 = 0.07).</p>
</sec>
<sec id="acr211106-sec-0004"><title>Conclusion</title>
<p>The uptake of biosimilars in the United States remains low despite persistence on infliximab‐dyyb being similar to the infliximab bio‐originator. These results add to clinical studies that should provide greater confidence to patients and physicians regarding biosimilar use.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Bansback, Nick" sort="Bansback, Nick" uniqKey="Bansback N" first="Nick" last="Bansback">Nick Bansback</name>
<name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R." last="Curtis">Jeffrey R. Curtis</name>
<name sortKey="Evans, Michael" sort="Evans, Michael" uniqKey="Evans M" first="Michael" last="Evans">Michael Evans</name>
<name sortKey="He, Zeling" sort="He, Zeling" uniqKey="He Z" first="Zeling" last="He">Zeling He</name>
<name sortKey="Huang, Jie" sort="Huang, Jie" uniqKey="Huang J" first="Jie" last="Huang">Jie Huang</name>
<name sortKey="Johansson, Tracy" sort="Johansson, Tracy" uniqKey="Johansson T" first="Tracy" last="Johansson">Tracy Johansson</name>
<name sortKey="Liao, Katherine P" sort="Liao, Katherine P" uniqKey="Liao K" first="Katherine P." last="Liao">Katherine P. Liao</name>
<name sortKey="Michaud, Kaleb" sort="Michaud, Kaleb" uniqKey="Michaud K" first="Kaleb" last="Michaud">Kaleb Michaud</name>
<name sortKey="Schmajuk, Gabriela" sort="Schmajuk, Gabriela" uniqKey="Schmajuk G" first="Gabriela" last="Schmajuk">Gabriela Schmajuk</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000241 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000241 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:7011419
   |texte=   Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32043831" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a TocilizumabV1

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

Serveur d'exploration Tocilizumab

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.